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Both PON1 Q192R and CYP2C19*2 inﬂuence platelet response to clopidogrel
and ischemic events in Chinese patients undergoing percutaneous coronary
intervention
Chen Yu, Huang Xiaohong, Tang Yong, Xie Yuquan, Zhang Yachen
Xinhua Hospital, Shanghai Jiaotong University School of Medicine
Objectives: Clopidogrel nonresponsiveness increases the recurrence of cardiovascular
events of patients undergoing percutaneous coronary intervention (PCI). Genetic
variant is a major factor to inﬂuence clopidogrel response. In this study we investi-
gated the effects of genetic variants on clopidogrel response and clinical outcomes in
Chinese patients with PCI.
Methods: Acute coronary syndrome patients undergoing PCI were enrolled. The
platelet response to clopidogrel was detected by Thrombelastograph. High platelet
reactivity (HPR) was deﬁned as 70% adenosine diphosphate-induced aggregation.
10 single nucleotide polymorphisms (SNPs) (ABCB1, CYP2C19*2, CYP2C19*3,
CYP2C19*4, CYP2C19*17, CYP3A4, CYP3A5, ITGB3, P2Y12 and PON1 Q192R)
were detected by the Sequenom MassARRAY platform. The clinical endpoint was the
incidence of major adverse cardiovascular event (MACE), including cardiovascular
death, myocardium infarction, target vessel revascularization, stent thrombosis and
stroke. The follow-up duration was 6 months.
Results: Among 336 patients included, 53 (15.77%) were categorized as HPRs.
CYP2C19*4 and P2Y12 variants did not be found in our population. PON1 192Q
and CYP2C19*2 alleles were signiﬁcantly higher in HPR than normal platelet
reactivity (NPR) group (P¼0.033 and 0.038, respectively); while the other SNPs
were not signiﬁcantly different between the two groups. The platelet aggregation
of PON1 192Q carrier was signiﬁcantly higher than non-carrier both at baseline and
1 month after PCI (P¼0.010 and 0.024, respectively), and so did CYP2C19*2
carrier (P¼0.005 and 0.003, respectively). The risks of MACE increased with PON1
192Q and CYP2C19*2 alleles during 6-month follow-up (P¼0.012 and 0.003,
respectively).
Conclusions: Both PON1 192Q and CYP2C19*2 alleles are associated with HPR and
increased risk of ischemic events in Chinese patients undergoing PCI.
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Novel therapy for Distal Extremity Artery Occlusion by Argatroban Combined
with Alprostadil
Fan Fenling
Department of Cardiovascular Medicine, the 1st Hospital of Xi’an Jiaotong
University
Objectives: Distal extremity arterial occlusion is common among peripheral arterial
disease (PAD), which is alone or combined with proximal extremity arterial lesion,
particularly in elder and terminal renal disease or diabetes patients. However, poor
prospective results, even impossibility are from angioplasty so that the incidence of
amputation quite high in the severe cases. Medication, generally including Heparin or
Low Molecular Weight Heparin (LMWH), anti-platelet and vascular dilation is not
only primary but also main therapy for treatment of those patients though the
effects also are less satisﬁed in clinic so far. Hence, the better strategies for treatment
of distal extremity arterial occlusion are desirable. Argatroban, a small molecule
direct thrombin inhibitor, not only inhibits the free clot but also bound thrombin with
ﬁne safety as it is metabolized through liver and APTT monitorable. The purpose of
this study is assessing the clinic effects of argatroban on distal extremity arterial
occlusion.
Methods: 79 age and gender matched adults with distal arterial occlusion were
randomly enrolled into two groups: study group (n¼42): intravenous injected arga-
troban 10mg BID combined with PGE1, Alprostadil, 10ug BID for 10days; Control
group (n¼39): subcutaneous injected LMWH, Enoxaparin, 4000u Q12H combined
with intravenous injected Alprostadil 10ug BID for 10days. Pain, Ulcer, ABI, TBI,
Bleeding and endpoints and their degrees were described with different scores which
recorded before, 5-15-30 days after treatment. [Pain Score (0. Asymptomatic, (1)
Reduced Cool or numb feeling or speciﬁc slight distal legs or feet pain, (2) Claudi-
cation at a distance 200m, (3) Claudication distance of < 200m, (4) Most daily rest
pain, (5) Most night pain); Ulcer Score (0. No skin color change 1. pale or purple feet,
2. Ulcers limited in 1 or 1 ﬁnger, 3. Ulcers limited in 2 or 2 ﬁngers, 4. Ulcers limited in
3 or 3 ﬁngers, 5. Ulcers limited in 4 or 4 ﬁngers, 6. Ulcers about 5 or in 5 ﬁngers, 7.
Ulcers more than 5 or in whole feet); ABI Score (1. 0.50-0.90, 2. 0.21-0.49, 3.< 0.21);
TBI Score(1. 0.5-0.7, 2. 0.35-0.5, 3. <0.35 or toe pressure<40 mmHg, 4. <0.35 or toe
pressure < 30 mmHg); Bleeding Score (0. No bleeding, -1.mild bleeding, -2.moderate
bleeding, -3.severe bleeding); End points (0. No amputation; -1. amputation; -2 died) ].
The difference between scores before and after treatment (5-15-30 days respectively)
used for analysis of clinic improvements.
Results: The total scores of all observed items was signiﬁcantly decreased in study
group than that of control group in the 15th day after medication (21.2810.12 vs.
29.6312.58; P<0.05). Individual items including Painess Score (2.181.13 vs
2.641.53;P<0.05), Ulcer Score (2.761.51 vs 3.241.58;P<0.05), TBI
Score (2.201.38 vs. 2.821.80;P<0.05) and Bleeding Score (-0.230..43 vs
-0.540.78;P<0.05) are signiﬁcantly different between two groups too, whereas
there were no statistically different in ABI Score (1.360.74 vs. 1.270.83;P>0.05)
and Endpoints (-0.230.42 vs. -0.240.58; P>0.05) in the 15th day after
medication.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CConclusions: A signiﬁcant further improvement in the clinic indexes of patient with
distal arterial occlusion using PGE1 combined with direct thrombin inhibitor than that
with LMWH A signiﬁcant further improvement in the clinic indexes of patient with
distal arterial occlusion using PGE1 combined with direct thrombin inhibitor than that
with LMWH.
GW25-e0718
Plasma LDL-C goal achievement with Atorvastatin Monotherapy versus
Atorvastatin and Probucol combination therapy in patients with coronary
atherosclerosis
Adhikari Binaykumar, Zhang Sisi, Xiaoping Meng
Cardiology Department, Second Hospital of Jilin University
Objectives: Major objective is to evaluate the extent to reach LDL-C goal by
intensive statin therapy and standard statin therapy with or without probucol in
coroanry atherosclerotic patients and compare between groups in the extent of
achieving LDL-C goal. Secondary objective is to study the effect of therapies on blood
triglycerides, total cholesterol, high density lipoprotein, blood glucose and liver
enzymes.
Methods: A total of 200 patients who visited OPD and IPD of Cardiology Depart-
ment, Second Hospital of Jilin Unviersity were assessed for eligibility. Mean age was
56.35+-8.798 years, with 56% males, and 44% females. Inclusion criteria were age
ranged from 35 to 75 years, stenosis of one of branches of coronary artery between
20% to 50%, and LDL-C level >2.5 mmol/L. Exlucsion criteria were acute coronary
syndrome, diabetes mellitus, abnormal liver and kidney function, heart failure.
Patients were randomly divided into 4 groups; standard treatment group: ﬁrst group
aspirin/A, statin/S (AS group), and second group probucol/P, aspirin/A, statin/S (PAS
group). Standard dose was aspirin 100 mg, atorvastatin 20 mg, and probucol 0.5 g. All
data were analyzed using SPSS 21.0 software. A P value <0.05 was considered
statistically signiﬁcant, P value >0.05 was considered statistically insigniﬁcant.
Results: In 20 mg AS group, 14 out of 48 patients i.e. 33% patients achieved LDL-C
goal of <1.8 mmol/L, while in 20 mg PAS group, 24 out of 39 patients i.e. 61.5%
patients; in 40 mg AS group, 23 out of 36 patients i.e. 63.88% patients; and in 40 mg
PAS group, 41 out of 52 patients i.e. 78.8% patients achieved the goal of LDL-C<1.8
mmol/L. Comparing intensive statin AS group with standard statin AS group, there is
statistical signiﬁcance in achieving LDL-C goal (P¼0.000). But, comparing intensive
statin PAS with statndard statin PAS, there is no statistical signiﬁcance in achieving
LDL-C goal (P¼0.279). There is no statistical signiﬁcance between intensive statin
PAS group and intensive statin AS group (P¼0.148). Regarding effect on HDL-C, no
matter standard statin therapy or intensive statin therapy, there is not statistical sig-
niﬁcance. When probucol is added to intesive statin therapy, HDL-C decreased by
18.10%, with statistical signiﬁcace (P¼0.000).
Conclusions: From the statin dose point of view, we think, atorvastatin 40 mg has
higher rate of achieving LDL-C goal of <1.8 mmol/L than standard statin dose by
30.8%. Comparing intensive PAS group with intensive AS group, rate of LDL-C goal
of <1.8 mmol/L is higher by 15%, that means antioxidant probucl has synergic
effect. Probucol signiﬁcantly decreases high density lipoprotein, hence cautiously
presciribed to patients with low HDL-C level. Besides one case who had liver
enzymes elevated 3 times upper normal limit, there were no cases of other adverse
effects, no case of cardiovascular events, hence intensive lipid lowering therapy is
quite safe.
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Catheter directed thrombolysis along with mechanical thromboaspiration versus
anticoagulation alone in the management of lower limb deep venous thrombosis-
A comparative study
Soumya Patra
SJICR, Bangalore, India
Objectives: Catheter-directed thrombolysis (CDT) with assisted mechanical throm-
bolysis is now considered as the standard of medical care for deep vein thrombosis
(DVT). The study was to describe the immediate & long term (six months) safety and
effectiveness of CDT in patient with lower limb DVT compared with the routine
anticoagulation alone.
Methods: All 12-85 years old patients with recent (0-8 weeks) DVT were included. In
CDT group, thrombus was aspirated mechanically and streptokinase was given along
with unfractioned heparin (UFH). After 6 months, deep venous patency and post-
thrombophlebitic syndrome (PTS) was assessed by using duplex ultrasound and
Villalta scale, respectively.
Results: Among 51 patients with completed data, 25 patients were allocated addi-
tional CDT given for a mean duration of 108+/-32 hours and 26 patients were allo-
cated standard treatment alone. Grade III (complete) lysis was achieved in 37%) and
grade II (50%-90%) lysis in 63% of patients. Patients with partial lysis underwent
percutaneous transluminal angioplasty and/ or venous stenting. After 6 months, ilio-
femoral patency was found in 20 (80%) in the CDT group vs. 7 (23%) in anti-
coagulation alone group (P<0.01). PTS was seen in 5 (20%) in the CDT group vs. 19
(77%) in anticoagulation alone group (P<0.01).
Conclusions: We conclude that CDT and conventional manual aspiration throm-
bectomy is an effective treatment for lower extremity DVT. Streptokinase infusion can
be safely given up to 6 days. As addition of UFH can cause thrombocytopenia, so
daily monitoring of complete blood counts is needed during CDT.ardiovascular Disease Clinical Research C203
